Attaya Suvannasankha

lingue parlate o scritte: inglese

scuola frequentata: Università Chulalongkorn

occupazione: professore universitario, ricercatore

sito web ufficiale: medicine.iu.edu/faculty/5033/suvannasankha-attaya

Serie

There is nothing here

Crea una nuova serie

Opere

There is nothing here

Crea un nuovo lavoro

Articoli 31

Data

Titolo

Autori

2019-01-01

Acquired Factor X Deficiency in Patients With Primary Light Chain Amyloidosis

Siroj Dejhansathit, Attaya Suvannasankha
2019-12-16

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

Thierry Facon, Paul G. Richardson, Philippe Moreau, Katja Weisel, Suzanne Trudel, Attaya Suvannasankha, Saad Z Usmani, Bertrand Arnulf, Ashraf Z Badros, Lionel Karlin, Rachid Baz, K Martin Kortüm, Ajay K Nooka, Parameswaran Hari, Sagar Lonial, Ajai Chari, Paula Rodríguez-Otero, Hang Quach
2018-06-19

The Role of Semaphorin 4D in Bone Remodeling and Cancer Metastasis

Deborah L. Galson, Attaya Suvannasankha
2017-06-21

Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma

Sagar Lonial, Attaya Suvannasankha
2017-10-04

Multifocal myeloid sarcomas: a rare presentation of AML.

Attaya Suvannasankha
2017-12-25

Consecutive epigenetically-active agent combinations act in ID1-RUNX3-TET2 and HOXA pathways for Flt3ITD+ve AML.

Attaya Suvannasankha
2016-10-01

Multifocal Gastric Ulcers Caused by Diffuse Large B Cell Lymphoma in a Patient With Significant Weight Loss

Attaya Suvannasankha
2016-09-07

Cell Adhesion Molecule CD166 Drives Malignant Progression and Osteolytic Disease in Multiple Myeloma.

Melissa A. Kacena, Attaya Suvannasankha, Edward F Srour
2015-04-12

FGF23 is elevated in multiple myeloma and increases heparanase expression by tumor cells

Attaya Suvannasankha
2015-07-21

Targeted nuclear factor-kappaB suppression enhances gemcitabine response in human pancreatic tumor cell line murine xenografts

Joal D Beane, Michele T. Yip-Schneider, Attaya Suvannasankha
2014

Role of bone-anabolic agents in the treatment of breast cancer bone metastases

Attaya Suvannasankha
2014-12-02

Tumor-expressed adrenomedullin accelerates breast cancer bone metastasis

Theresa A. Guise, Attaya Suvannasankha
2014-06-28

Regulation of ubiquitin-proteasome system-mediated Tip110 protein degradation by USP15.

Khalid Amine Timani, Attaya Suvannasankha
2013-03-27

Temozolomide-mediated DNA methylation in human myeloid precursor cells: differential involvement of intrinsic and extrinsic apoptotic pathways

Karen E. Pollok, Attaya Suvannasankha, Magdalena B. Czader
2013-08-27

Comparison of an assumption-free Bayesian approach with Optimal Sampling Schedule to a maximum a posteriori Approach for Personalizing Cyclophosphamide Dosing

Attaya Suvannasankha
2013-04-03

Validation of a novel approach for dose individualization in pharmacotherapy using gabapentin in a proof of principles study

Attaya Suvannasankha
2012-10-01

A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma

Michael A Caligiuri, Attaya Suvannasankha
2011-11-17

A noncanonical Flt3ITD/NF-κB signaling pathway represses DAPK1 in acute myeloid leukemia

Attaya Suvannasankha
2010-12-01

The novel histone deacetylase inhibitor, AR-42, inhibits gp130/Stat3 pathway and induces apoptosis and cell cycle arrest in multiple myeloma cells

Attaya Suvannasankha
2010-06-15

Preclinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD-2076, against multiple myeloma

Karen E. Pollok, Attaya Suvannasankha, George E. Sandusky
2008-03-01

Antimyeloma effects of a sesquiterpene lactone parthenolide

Harikrishna Nakshatri, Attaya Suvannasankha
2008-04-29

Deep vein thrombosis and pulmonary embolism in cirrhosis patients

Attaya Suvannasankha
2008-10-01

Gastrointestinal plasmacytoma presenting as gastrointestinal bleeding

Attaya Suvannasankha
2007-08-01

OSU-03012, a novel celecoxib derivative, is cytotoxic to myeloma cells and acts through multiple mechanisms

Attaya Suvannasankha
2007-01-01

Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patients with relapsed or refractory multiple myeloma: A Hoosier Oncology Group Trial, HEM01-21.

Constantin T Yiannoutsos, Attaya Suvannasankha
2006-10

Constitutive c-jun N-terminal kinase activity in acute myeloid leukemia derives from Flt3 and affects survival and proliferation

Attaya Suvannasankha
2006-09-01

Weekly bortezomib/methylprednisolone is effective and well tolerated in relapsed multiple myeloma

Attaya Suvannasankha
2004-11-01

Breast cancer resistance protein (BCRP/MXR/ABCG2) in adult acute lymphoblastic leukaemia: frequent expression and possible correlation with shorter disease-free survival

Takeo Nakanishi, Attaya Suvannasankha
2004-05-01

Expression of the neural cell adhesion molecule CD56 is not associated with P-glycoprotein overexpression in core-binding factor acute myeloid leukemia.

Attaya Suvannasankha
2003-05-01

Terbinafine-associated hepatotoxicity

Attaya Suvannasankha
2002-06-01

Flow cytometric analysis of breast cancer resistance protein expression and function

Rob Robey, Attaya Suvannasankha

Human - wd:Q91794495

Benvenuto su Inventaire

la biblioteca dei tuoi amici e della tua comunità

ulteriori informazioni